BCDA
BioCardia, Inc.
NASDAQ · USHealthcareBiotechnology
$0.90+9.57%
Price as of Jul 20, 2026
BCDA financials
BioCardia, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $58.0K | $477.0K | $1.4M |
| Cost of revenue | $505.0K | $4.4M | $7.7M | $8.8M |
| Gross profit | -$505.0K | -$4.3M | -$7.2M | -$7.5M |
| Operating expenses | $7.8M | $3.7M | $4.4M | $4.4M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M |
| EBITDA | -$7.7M | -$7.9M | -$11.5M | -$11.8M |
| Basic EPS | $-1.23 | $-2.90 | $-8.19 | $-10.05 |
| Diluted EPS | $-1.23 | $-2.90 | $-8.19 | $-10.05 |
| Balance sheet | ||||
| Cash & equivalents | $2.5M | $2.4M | $1.1M | $7.4M |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M |
| Stockholders’ equity | $895.0K | $837.0K | -$1.6M | $4.9M |
| Total debt | $528.0K | $951.0K | $1.3M | $1.6M |
| Net debt | -$2.0M | -$1.4M | $212.0K | -$5.7M |
| Cash flow | ||||
| Operating cash flow | -$7.4M | -$8.0M | -$10.0M | -$10.6M |
| Capital expenditure | -$7.0K | -$6.0K | -$12.0K | -$70.0K |
| Free cash flow | -$7.4M | -$8.0M | -$10.0M | -$10.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |